Mirae Asset Global Investments Co. Ltd. Has $522,000 Stock Position in Kura Oncology, Inc. (NASDAQ:KURA)

Mirae Asset Global Investments Co. Ltd. cut its stake in shares of Kura Oncology, Inc. (NASDAQ:KURA) by 5.7% in the fourth quarter, Holdings Channel reports. The firm owned 36,311 shares of the company’s stock after selling 2,207 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Kura Oncology were worth $522,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Pale Fire Capital SE bought a new position in Kura Oncology during the third quarter worth about $92,000. E Fund Management Co. Ltd. raised its position in shares of Kura Oncology by 12.2% in the 3rd quarter. E Fund Management Co. Ltd. now owns 11,929 shares of the company’s stock valued at $109,000 after acquiring an additional 1,301 shares during the period. AXQ Capital LP bought a new position in Kura Oncology during the 3rd quarter worth approximately $118,000. China Universal Asset Management Co. Ltd. grew its holdings in Kura Oncology by 352.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,590 shares of the company’s stock valued at $124,000 after purchasing an additional 6,692 shares during the period. Finally, Teacher Retirement System of Texas grew its holdings in Kura Oncology by 11.1% during the third quarter. Teacher Retirement System of Texas now owns 15,490 shares of the company’s stock valued at $141,000 after purchasing an additional 1,544 shares during the period.

Wall Street Analysts Forecast Growth

KURA has been the topic of a number of recent analyst reports. StockNews.com cut shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Monday, April 15th. HC Wainwright reiterated a “buy” rating and set a $32.00 target price on shares of Kura Oncology in a report on Monday. JMP Securities increased their price target on Kura Oncology from $22.00 to $32.00 and gave the stock a “market outperform” rating in a report on Wednesday, January 31st. Finally, Wedbush reaffirmed an “outperform” rating and set a $37.00 price target on shares of Kura Oncology in a research report on Wednesday, February 28th. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $28.28.

Kura Oncology Stock Up 1.3 %

KURA stock opened at $19.00 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 12.26 and a quick ratio of 12.26. The stock has a market capitalization of $1.45 billion, a P/E ratio of -9.13 and a beta of 0.85. Kura Oncology, Inc. has a fifty-two week low of $7.41 and a fifty-two week high of $24.17. The business has a 50-day moving average of $20.70 and a 200-day moving average of $15.44.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Tuesday, February 27th. The company reported ($0.55) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.01. During the same period last year, the company posted ($0.49) EPS. On average, sell-side analysts anticipate that Kura Oncology, Inc. will post -2.35 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Kura Oncology news, insider Teresa Brophy Bair sold 2,053 shares of Kura Oncology stock in a transaction on Monday, January 29th. The shares were sold at an average price of $17.80, for a total value of $36,543.40. Following the sale, the insider now directly owns 68,979 shares in the company, valued at approximately $1,227,826.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, COO Kathleen Ford sold 1,496 shares of the stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $17.80, for a total value of $26,628.80. Following the completion of the sale, the chief operating officer now owns 21,602 shares of the company’s stock, valued at approximately $384,515.60. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Teresa Brophy Bair sold 2,053 shares of the firm’s stock in a transaction on Monday, January 29th. The shares were sold at an average price of $17.80, for a total transaction of $36,543.40. Following the completion of the transaction, the insider now directly owns 68,979 shares of the company’s stock, valued at $1,227,826.20. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 5,867 shares of company stock worth $104,433. 5.50% of the stock is owned by insiders.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.